Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer Business Review India (press release) SAN DIEGO, July 3, 2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a developer of trans-renal molecular diagnostics, announced today that they will be collaborating with The University of Texas MD Anderson Cancer Center on the detection of ... |
